Detalles de la búsqueda
1.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Lancet
; 398(10315): 1984-1996, 2021 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34767764
2.
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Clin Immunol
; 191: 10-20, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29518577
3.
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib.
Ann Rheum Dis
; 79(5): 669-671, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32161057
4.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 47(3): 419-429, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35226304
5.
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Int J Rheum Dis
; 23(7): 882-897, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32478474
6.
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Arthritis Rheumatol
; 69(10): 1969-1977, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28845577
7.
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
Vaccine
; 31(12): 1569-75, 2013 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23352429
Resultados
1 -
7
de 7
1
Próxima >
>>